v3.26.1
Reverse Recapitalization and Sonnet Acquisition (Details Narrative) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended
Mar. 31, 2026
Jul. 11, 2025
Mar. 31, 2026
Dec. 02, 2025
Jun. 30, 2025
Business Combination [Line Items]          
Common stock, par or stated value per share $ 0.01   $ 0.01   $ 0.01
Stock issued during period, value, new issues     $ 1,470    
Asset Purchase Agreement [Member]          
Business Combination [Line Items]          
cash transactions $ 1,325   1,325    
deferred purchase price 1,000   $ 1,000    
Services fees expense $ 175        
Common Stock [Member]          
Business Combination [Line Items]          
Common stock, par or stated value per share       $ 0.01  
Stock issued during period, shares, new issues     252,600    
Stock issued during period, value, new issues     $ 3    
Rorschach Advisors LLC [Member]          
Business Combination [Line Items]          
Number of cryptocurrency token   12.5      
Cryptocurrency token value   $ 411,300      
Loss on commitment on cryptocurrency token   $ 169,200      
Rorschach Advisors LLC [Member] | Common Stock [Member]          
Business Combination [Line Items]          
Common stock, par or stated value per share   $ 1.25      
Stock issued during period, shares, new issues   7,761,860      
Rorschach and Sonnet Merger [Member]          
Business Combination [Line Items]          
Number of cryptocurrency token   12.5      
Rorschach and Sonnet Merger [Member] | Common Stock [Member]          
Business Combination [Line Items]          
Stock issued during period, value, new issues   $ 299,900      
Sonnet BioTherapeutics Holdings, Inc. [Member]          
Business Combination [Line Items]          
Stock issued during period, shares, new issues   3,680,346      
Stock issued during period, value, new issues   $ 17,800      
Total cost of the acquisition   44,834      
Transaction costs   9,324      
Sonnet BioTherapeutics Holdings, Inc. [Member] | Common Stock [Member]          
Business Combination [Line Items]          
Stock issued during period, value, new issues   $ 17,771      
Sonnet BioTherapeutics Holdings, Inc. [Member] | Warrant [Member]          
Business Combination [Line Items]          
Stock issued during period, shares, new issues   2,400,000      
Stock issued during period, value, new issues   $ 12,478      
Cash payment to settle outstanding warrants   $ 5,261      
Guidant Bio Therapeutics Inc. [Member] | Asset Purchase Agreement [Member]          
Business Combination [Line Items]          
percentage of common stock interest 40.00%   40.00%